Online citations, reference lists, and bibliographies.
← Back to Search

Side Effects Of Adjuvant Treatment Of Breast Cancer.

C. Shapiro, A. Recht
Published 2001 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Women with primary invasive breast cancer receive both local and systemic treatment. Surgery and radiation therapy are local treatments given to reduce the risk of recurrent cancer in the breast, chest wall, and regional lymph nodes. In some cases, these local treatments may prevent the dissemination of cancer and may reduce mortality from breast cancer. Cytotoxic chemotherapy and hormonal therapy are systemic treatments given after local treatment to reduce systemic recurrences and overall mortality from breast cancer. Recent guidelines from the National Institutes of Health Consensus Conference, the National Comprehensive Cancer Center Network, and other groups recommend adjuvant chemotherapy, tamoxifen, . . .
This paper references
10.2165/00126839-199902040-00001
Antiemetics for Cancer Chemotherapy—Induced Nausea and Vomiting
A. Rizk (1999)
10.1016/S0140-6736(99)05036-9
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
B. Fisher (1999)
10.7326/0003-4819-126-10-199705150-00008
Medicinal Applications of Delta-9-Tetrahydrocannabinol and Marijuana
E. Voth (1997)
10.1200/JCO.1998.16.2.487
Long-term quality of life after breast cancer: comparison of 8-year survivors with population controls.
M. Dorval (1998)
10.7326/0003-4819-115-11-860
Effects of tamoxifen on cardiovascular risk factors in postmenopausal women.
R. Love (1991)
10.1200/JCO.1989.7.1.21
Leukemia risk following radiotherapy for breast cancer.
R. Curtis (1989)
10.1016/0360-3016(91)90783-Z
Long-term risk of sarcoma following radiation treatment for breast cancer.
A. Taghian (1991)
10.1016/S0167-8140(98)00062-0
Long-term cardiac morbidity and mortality in a randomized trial of pre- and postoperative radiation therapy versus surgery alone in primary breast cancer.
G. Gyenes (1998)
10.1007/978-3-642-45769-2_38
Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors.
P. Ganz (1998)
10.1093/JNCI/85.17.1398
Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group.
L. Rutqvist (1993)
10.1200/JCO.1996.14.10.2731
Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.
K. Pritchard (1996)
10.1200/JCO.2000.18.22.3758
Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group.
J. Nabholtz (2000)
10.1016/S0360-3016(97)00765-7
Myocardial infarction among women with early-stage breast cancer treated with conservative surgery and breast irradiation.
L. Rutqvist (1998)
10.1093/AJCN/65.5.1495
Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy.
W. Demark-Wahnefried (1997)
10.1002/(SICI)1097-0142(19990201)85:3<640::AID-CNCR14>3.0.CO;2-G
Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma
S. Schagen (1999)
10.1056/NEJM199203263261302
Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.
R. Love (1992)
10.1200/JCO.2001.19.1.37
Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation.
M. Zambetti (2001)
10.3322/canjclin.47.3.134
Twenty‐year follow‐up of the breast cancers diagnosed during the Breast Cancer Detection Demonstration Project
C. Smart (1997)
10.1200/JCO.1995.13.5.1144
Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up.
C. Quiet (1995)
10.7326/0003-4819-128-2-199801150-00007
Radiation Therapy for Breast Cancer and Increased Risk for Esophageal Carcinoma
H. Ahsan (1998)
10.1097/00000421-198904000-00007
Ten‐Year Results of FAC Adjuvant Chemotherapy Trial in Breast Cancer
A. Buzdar (1989)
10.1200/JCO.1996.14.3.1018
Tamoxifen-associated eye disease. A review.
S. Nayfield (1996)
10.1016/0360-3016(91)90782-Y
Radiation pneumonitis in breast cancer patients treated with conservative surgery and radiation therapy.
T. Lingos (1991)
10.1200/JCO.1994.12.1.155
Transdermal clonidine for ameliorating tamoxifen-induced hot flashes.
R. Goldberg (1994)
10.1200/JCO.2000.18.4.743
Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life.
J. Bower (2000)
10.1080/07357909909011727
Taxanes in the treatment of breast cancer: a prodigy comes of age.
K. Miller (1999)
10.1200/JCO.1999.17.9.2659
Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
R. Day (1999)
10.1200/JCO.1998.16.2.495
Prospective evaluation of vitamin E for hot flashes in breast cancer survivors.
D. Barton (1998)
10.1200/JCO.1999.17.1.120
Adjuvant treatment and onset of menopause predict weight gain after breast cancer diagnosis.
P. Goodwin (1999)
10.1200/JCO.1990.8.8.1327
Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer.
J. Camoriano (1990)
10.1002/1097-0142(19951101)76:9<1491::AID-CNCR2820760902>3.0.CO;2-8
Axillary lymph nodes and breast cancer. A review
A. Recht (1995)
10.1016/0360-3016(92)90895-O
Long-term radiation complications following conservative surgery (CS) and radiation therapy (RT) in patients with early stage breast cancer.
S. M. Pierce (1992)
10.1056/NEJM199408113310602
Megestrol acetate for the prevention of hot flashes.
C. Loprinzi (1994)
10.1016/0378-5122(88)90166-1
Long-term adjuvant therapy with tamoxifen: effects on sex hormone binding globulin and antithrombin III.
V. Jordan (1987)
10.1001/JAMA.1995.03520310040027
Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results.
G. Bonadonna (1995)
10.1056/NEJM199206253262605
Risk of leukemia after chemotherapy and radiation treatment for breast cancer.
R. Curtis (1992)
10.1200/JCO.2000.18.20.3558
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.
H. Ozer (2000)
10.1200/JCO.1999.17.8.2365
Risk of menopause during the first year after breast cancer diagnosis.
P. Goodwin (1999)
10.1056/NEJM199710023371402
Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer.
J. Ragaz (1997)
10.1093/JNCI/90.9.704
Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer.
T. Powles (1998)
10.1200/JCO.2000.18.5.1068
Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial.
S. Quella (2000)
10.1097/00000421-198606000-00018
Second Neoplasms After Adjuvant Chemotherapy for Operable Breast Cancer
M. Herring (1986)
10.1007/978-3-642-82357-2_24
Second malignant neoplasms in operable carcinoma of the breast.
E. Holdener (1984)
10.1200/JCO.1993.11.7.1418
Why women gain weight with adjuvant chemotherapy for breast cancer.
W. Demark-Wahnefried (1993)
10.1056/NEJM199405053301801
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.
W. Wood (1994)
10.1200/JCO.1998.16.4.1374
No long-term increase in cardiac-related mortality after breast-conserving surgery and radiation therapy using modern techniques.
A. Nixon (1998)
10.1200/JCO.1990.8.9.1483
Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe
B. Fisher (1990)
10.1093/OXFORDJOURNALS.ANNONC.A010566
Risk of new primaries after chemotherapy and/or tamoxifen treatment for early breast cancer.
A. Rubagotti (1996)
10.1093/JNCI/90.21.1601
Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.
A. Goldhirsch (1998)
10.1001/JAMA.272.7.540
Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group.
M. Cobleigh (1994)
10.1200/JCO.1997.15.4.1341
Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.
T. Saarto (1997)
10.1056/NEJM198902233200802
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.
B. Fisher (1989)
10.1001/JAMA.1979.03300140025017
Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report.
A. Buzdar (1979)
10.1002/1097-0142(19930515)71:10<3054::AID-CNCR2820711027>3.0.CO;2-N
Lung cancer after radiation therapy for breast cancer
Alfred I. Neugut (1993)
10.1200/JCO.1999.17.5.1482
Estrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively.
R. Vassilopoulou-sellin (1999)
10.1056/NEJM199612123352401
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
G. Hortobagyi (1996)
10.1200/JCO.1995.13.11.2737
Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy.
R. Couzi (1995)
10.1016/S0140-6736(97)11423-4
Tamoxifen for early breast cancer: An overview of the randomised trials
O. Abe (1998)
10.1200/JCO.1995.13.7.1557
Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience.
M. Tallman (1995)
10.1016/0360-3016(85)90179-8
Dose to the contralateral breast due to primary breast irradiation.
B. Fraass (1985)
10.1016/0167-8140(92)90263-T
Multidisciplinary treatment approach to locally advanced non-inflammatory breast cancer using chemotherapy and radiotherapy with or without surgery.
E. Touboul (1992)
10.1093/JNCI/87.9.645
Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group.
L. Rutqvist (1995)
10.1016/0140-6736(91)91100-9
Adjuvant chemotherapy in early breast cancer and incidence of new primary malignancies
R. Arriagada (1991)
10.1056/NEJM199710023371401
Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.
M. Overgaard (1997)
10.1016/S0002-9378(99)70550-8
Estrogen replacement therapy in women with previous breast cancer.
P. K. Natrajan (1999)
10.1136/bmj.311.7011.977
Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial
C. C. McDonald (1995)
10.1056/NEJM199208063270614
Cancer in the contralateral breast after radiotherapy for breast cancer.
J. Boice (1992)
10.1093/JNCI/90.3.210
Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy.
F. V. van Dam (1998)
10.1200/JCO.1997.15.3.969
Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer.
C. L. Loprinzi (1997)
10.1038/bjc.1992.430
The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial.
C. Blomqvist (1992)
10.1038/bjc.1992.350
Haemostatic changes and thromboembolic risk during tamoxifen therapy in normal women.
A. Jones (1992)
10.1016/S0889-8588(18)30191-6
Paclitaxel (Taxol) in breast cancer.
S. Arbuck (1994)
10.7326/0003-4819-85-4-447
Menopause and Risk of Cardiovascular Disease: The Framingham Study
W. Kannel (1976)
10.1007/BF00665973
Protein S and protein C level changes with adjuvant tamoxifen therapy in postmenopausal women
C. C. Mamby (2004)
10.1001/JAMA.281.23.2189
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
S. Cummings (1999)
10.7326/0003-4819-132-10-200005160-00004
Oral Clonidine in Postmenopausal Patients with Breast Cancer Experiencing Tamoxifen-Induced Hot Flashes: A University of Rochester Cancer Center Community Clinical Oncology Program Study
K. Pandya (2000)
Cardiotoxicity in patients receiving transtuzumab (Herceptin): primary toxicity, synergistic or sequential stress, or surveillance artifact?
M. Ewer (1999)
10.1200/JCO.1997.15.3.955
Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.
P. Delmas (1997)
10.1200/JCO.1995.13.11.2688
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
L. Gianni (1995)
10.1093/OXFORDJOURNALS.ANNONC.A058795
Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer.
P. Valagussa (1994)
10.1093/JNCI/70.5.797
A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the effect of radiation therapy.
B. Hankey (1983)
10.1200/JCO.1991.9.9.1650
Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study.
P. Rosen (1991)
10.1056/NEJM199712043372301
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
P. Delmas (1997)
10.1200/JCO.1996.14.10.2722
Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience.
E. Diamandidou (1996)
10.1038/bjc.1986.201
Risk of contralateral breast cancer in Denmark 1943-80.
H. Storm (1986)
10.1200/JCO.1989.7.3.355
A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma.
P. Rosen (1989)
10.1200/JCO.1996.14.5.1718
Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.
J. Bines (1996)
10.1200/JCO.1999.17.5.1488
Effect of tamoxifen on sexual functioning in patients with breast cancer.
J. Mortimer (1999)
10.1200/JCO.2000.18.22.3748
Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study.
J. Bonneterre (2000)
10.1200/JCO.1998.16.5.1689
Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer.
J. A. Broeckel (1998)
10.7326/0003-4819-125-1-199607010-00008
Anthracycline-Induced Cardiotoxicity
K. Shan (1996)
10.1200/JCO.1991.9.2.286
Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer.
T. Saphner (1991)
10.1002/(SICI)1097-0142(19990115)85:2<418::AID-CNCR20>3.0.CO;2-9
Quality of life of African‐American and white long term breast carcinoma survivors
K. Ashing-Giwa (1999)
10.1200/JCO.1996.14.1.78
Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women.
T. Powles (1996)
10.1093/JNCI/86.7.527
Endometrial Cancer in Tamoxifen-Treated Breast Cancer Patients: Findings From the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14
M. Carcangiu (1994)
10.1093/OXFORDJOURNALS.ANNONC.A059008
Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer.
P. Valagussa (1994)
10.1002/(SICI)1097-0142(19981215)83:12B+<2821::AID-CNCR33>3.0.CO;2-G
Overview of treatment options and review of the current role and use of compression garments, intermittent pumps, and exercise in the management of lymphedema
M. Brennan (1998)
10.1200/JCO.1998.16.11.3493
Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients.
C. Shapiro (1998)
10.1001/JAMA.1994.03520070060039
Estrogen Replacement Therapy in Breast Cancer Survivors: A Time for Change
M. Cobleigh (1994)
10.1016/S0360-3016(98)00412-X
Mortality from myocardial infarction following postlumpectomy radiotherapy for breast cancer: a population-based study in Ontario, Canada.
L. Paszat (1999)
10.1200/JCO.1985.3.12.1640
Leukemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: the NSABP experience.
B. Fisher (1985)
10.1200/JCO.1998.16.8.2625
Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries.
L. Paszat (1998)
10.7326/0003-4819-131-2-199907200-00009
Surveillance for Endometrial Cancer in Women Receiving Tamoxifen
E. Suh-Burgmann (1999)
10.1200/JCO.1999.17.1.130
Elements of informed consent for hormone replacement therapy in patients with diagnosed breast cancer.
R. Chlebowski (1999)
10.1093/JNCI/90.18.1371
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
B. Fisher (1998)



This paper is referenced by
Avaliação da reserva ovariana em mulheres com câncer de mama submetidas à quimioterapia
Ângela Marcon D’Avila (2013)
10.1097/COC.0b013e318142c865
Competing Causes of Death for Women With Breast Cancer and Change Over Time From 1975 to 2003
Xianglin L. Du (2008)
10.1038/sj.bjc.6602985
Real-time RT–PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer
I. Benoy (2006)
10.1016/j.ijgo.2008.01.006
Progesterone‐only and non‐hormonal contraception in the breast cancer survivor: Joint review and committee opinion of the Society of Obstetricians and Gynaecologists of Canada and the Society of Gynecologic Oncologists of Canada
D. Provencher (2008)
10.1016/j.ejca.2012.04.024
Use of health-care services during chemotherapy for breast cancer.
J. M. Baena-Cañada (2012)
10.1186/s13048-015-0209-4
Age, anti-müllerian hormone, antral follicles count to predict amenorrhea or oligomenorrhea after chemotherapy with cyclophosphamide
Ângela Marcon D'Avila (2015)
Synthesis and Evaluation of Polysialic Acid- Polycaprolactone Based Micelles for Drug Delivery
W. Ryan (2015)
10.15279/KPBA.2019.24.3.111
Hypertriglyceridemia-induced Severe Necrotizing Pancreatitis Following Low Dose Tamoxifen Administration
Yong Ho Jang (2019)
10.1007/978-2-287-36073-2_8
Traitement adjuvant du cancer du sein n’exprimant pas HER2
J. Pierga (2007)
10.1155/2013/456409
Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review
J. Lao (2013)
10.1038/s41556-019-0276-7
Therapy resistance beyond cellular dormancy
Melanie Werner-Klein (2019)
10.1007/s10549-005-3380-2
Adjuvant Ovarian Suppression Versus Chemotherapy for Premenopausal, Hormone-responsive Breast Cancer: Quality of Life and Efficacy Tradeoffs
E. Elkin (2005)
Determinants of physical activity and quality of life in breast cancer survivors
S. White (2011)
10.1016/j.currproblcancer.2012.06.006
Nonsurgical adjunctive treatment and its effects on the axilla.
Alan A. Thomay (2012)
Effectiveness of Follow-Up for Breast Cancer Patients
R. Kokko (2006)
Contenu d'une brève intervention informationnelle pour les femmes atteintes d'un cancer du sein et leur conjoint : point de vue des deux partenaires du couple
S. Grenier (2012)
10.1385/MO:22:1:017
A descriptive study of second primary malignancies associated to breast cancer in a Mexican Hispanic population
S. Vidal-Millán (2005)
10.1021/jp3109094
Chromium(VI) but not chromium(III) species decrease mitoxantrone affinity to DNA.
A. Nowicka (2013)
10.20381/RUOR-21580
Living with a Stoma After Surgical Resection for Rectal Cancer: An Interpretive Phenomenological Study to Understand How Stomas Can Affect Physical Activity
Stephanie Saunders (2018)
10.1007/s10880-012-9317-0
Recruiting Young Adult Cancer Survivors for Behavioral Research
C. Rabin (2012)
10.1080/17446651.2018.1455498
Ovarian function, fertility and reproductive lifespan in cancer patients
Y. Jayasinghe (2018)
10.1152/AJPHEART.00801.2007
Effects of voluntary wheel running on cardiac function and myosin heavy chain in chemically gonadectomized rats.
D. Hydock (2007)
Investigations into the expression of sirtuins in breast cancer: in vivo and in vitro studies
S. Zino (2010)
10.1093/EUROPACE/EUM033
Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator.
Tomasz Rudziński (2007)
10.1186/1471-2407-10-42
'Pragmatic randomized controlled trial of individually prescribed exercise versus usual care in a heterogeneous cancer survivor population': A feasibility study PEACH Trial: Prescribed exercise after chemotherapy
J. M. Walsh (2009)
10.1007/s10865-017-9855-x
Chronic and episodic stress predict physical symptom bother following breast cancer diagnosis
Lauren N Harris (2017)
10.1080/13697130802657896
Pharmacology and clinical applications of selective estrogen receptor modulators
A. Nath (2009)
RATIONAL DRUG DESIGN: AN INFORMATION DRIVEN APPROACH TO THE DESIGN OF AN ANTHRACYCLINE ANALOG
C. R. Young (2009)
10.1080/09638288.2017.1283714
An exploratory qualitative study of the meaning and value of a running/walking program for women after a diagnosis of breast cancer
J. Brunet (2018)
10.1177/1078155220915767
Adverse drug reactions associated with chemotherapeutic agents used in breast cancer: Analysis of patients' online forums.
S. Assi (2020)
10.1007/s10637-009-9253-5
Suppression of in vivo tumor growth by using a biodegradable thermosensitive hydrogel polymer containing chemotherapeutic agent
M. K. Kwak (2009)
10.1200/JCO.2003.04.093
Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes.
K. Courneya (2003)
See more
Semantic Scholar Logo Some data provided by SemanticScholar